| Autor: |
Neroeva NV; Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia., Neroev VV; Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia., Chesnokova NB; Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia., Katargina LA; Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia., Pavlenko TA; Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia., Beznos OV; Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia., Ilyukhin PA; Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia., Utkina OA; Helmholtz National Medical Research Center of Eye Diseases, Moscow, Russia., Lagarkova MA; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Laktionov PP; Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia., Bogomazova AN; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia., Kharitonov AE; Federal Research and Clinical Center of Physical-Chemical Medicine, Moscow, Russia. |
| Abstrakt: |
Retinal diseases accompanied with the dysfunction or death of the retinal pigment epithelial (RPE) cells are widespread, hard to treat, and appear to be a leading case of visual loss and blindness among the persons older than 55 years. Transplantation of RPE cells derived from the induced pluripotent stem cells (IPSC-RPE) is a promising method of therapy for these diseases. To ensure the transplant survival instant follow-up is required. It can be based on biochemical analyses of tear fluid that can be easily non-invasively collected. For the post-transplantation process monitoring we have choosen such polyfunctional bioregulators as α2-macroglobulin (α2-MG) and endothelin-1 (ET-1). RPE atrophy in New Zealand Albino rabbits was modeled via the subretinal injection of bevacizumab. IPSC-RPE in suspension or as a monolayer on the scaffold were transplanted subretinally 1 month after the injection. α2-MG activity and ET-1 concentration in tears were estimated during the first month and after 2, 3 and 7 months after transplantation. On the 7-14 days after transplantation α2-MG activity increased in tears of the both operated and controlateral eye probably as a reaction on the corticosteroid therapy. In 50% rabbits there was one more increase after 2-3 months that could be due to the immune inflammation. Concentration of ET-1 in tears decreased dramatically on the 7-14 days and 7 months after transplantation, and it could have an influence upon the retinal vassal tone. The data obtained show that estimation of bioregulators in tears can help monitoring local metabolic processes after RPE transplantation that is necessary for the opportune, reasonable and focused medicamental correction of post-transplantation process. |
